Amphastar Pharmaceuticals Inc (AMPH) reported quarterly earnings results on Monday, May-9-2016. The company said it had a profit of $0.12 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.15. Analysts had a consensus of $-0.03. The company posted revenue of $59.40 million in the period, compared to analysts expectations of $62.01 million. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.01 EPS.
Many Wall Street Analysts have commented on Amphastar Pharmaceuticals Inc. Amphastar Pharmaceuticals Inc was Initiated by Wells Fargo to “Outperform” on Feb 19, 2016.
Amphastar Pharmaceuticals Inc closed down -0.1 points or -0.85% at $11.72 with 2,13,546 shares getting traded on Friday. Post opening the session at $11.8, the shares hit an intraday low of $11.4084 and an intraday high of $12.05 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Apr 20, 2016, Diane G. Gerst (EVP, QA & Regulatory Affairs) sold 21,244 shares at $12.94 per share price. According to the SEC, on Mar 21, 2016, Richard K Prins (director) sold 2,400 shares at $11.25 per share price. On Dec 17, 2015, Rong Zhou (EVP, Production) sold 772 shares at $14.29 per share price, according to the Form-4 filing with the securities and exchange commission.
Amphastar Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing manufacturing marketing and selling technically-challenging generic and injectable and inhalation products. The Company has two operational segments: finished pharmaceutical products and active pharmaceutical ingredients (API products). The finished pharmaceutical products segment manufactures markets and distributes enoxaparin Cortrosyn naloxone lidocaine jelly as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 17 products and is developing a portfolio of approximately 13 generic and eight injectable and inhalation product candidates. In addition to its marketed products it has a pipeline of approximately 21 generic and product candidates in various stages of development which target a variety of indications.